Pharmaceutical co-crystals: A new opportunity in pharmaceutical science for a long-known but little-studied class of compounds

Polymorphism in Pharmaceutical Solids: Second Edition

Volumn , Issue , 2016, Pages 282-317

  Arora, Kapildev K ^a   Zaworotko, Michael J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995574953     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (175)

1. Haleblian JK. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci 1975; 64: 1269-88.
2. Byrn SR. Solid State Chemistry of Drugs, 2nd edn. SSCI Inc, 1999.
3. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977; 66: 1-19.
4. Bastin RJ, Bowker MJ, Slater BJ. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org Process Res Dev 2000; 4: 427-35.
5. Gould PL. Salt selection for basic drugs. Int J Pharm 1986; 33: 201-17.
6. Banerjee R, Bhatt PM, Ravindra NV, et al. Saccharin salts of active pharma ceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des 2005; 5: 2299-309.
7. Remenar JF, MacPhee JM, Larson BK, et al. Salt selection and simultaneous polymorphism assessment via high-throughput crystalliza tion: The case of Sertraline. Org Process Res Dev 2003; 7: 990-6.
8. Vishweshwar P, Beauchamp DA, Zaworotko MJ. An acetic acid solvate of trimesic acid that exhibits triple inclined interpenetration and mixed supramolecular homosynthons. Cryst Growth Des 2006; 6: 2429-31.
9. Banerjee R, Bhatt PM, Desiraju GR. Solvates of sildena fil saccharinate. A new host material. Cryst Growth Des 2006; 6: 1468-78.
10. Barnett SA, Tocher DA, Vickers M. The solvates of o-acetamidobenzamide. CrystEngComm 2006; 8: 313-19.
11. Hosokawa T, Datta S, Sheth AR, et al. Isostructurality among five solvates of phenylbutazone. Cryst Growth Des 2004; 4: 1195-201.
12. Desiraju GR. Supramolecular synthons in crystal engineering - a new organic synthesis. Angew Chem Int Ed 1995; 34: 2311-27.
13. Lehn J-M. Supramolecular Chemistry: Concepts and Perspectives. Weinheim: VCH, 1995.
14. Atwood JL, Davies JED, MacNicol DD, et al., eds. Comprehensive Supramolecular Chemistry, Vol 6. Oxford: Pergamon, 1996.
15. MacDonald JC, Whitesides GM. Solid-state structures of hydrogen-bonded tapes based on cyclic secondary diamides. Chem Rev 1994; 94: 2383-420.
16. Schmidt GMJ. Photodimerization in the solid state. Pure Appl Chem 1971; 27: 647-78.
17. Etter MC. A new role for hydrogen-bond acceptors in influencing packing patterns of carboxylic acids and amides. J Am Chem Soc 1982; 104: 1095-6.
18. Desiraju GR. Crystal Engineering: The Design of Organic Solids. Amsterdam: Elsevier, 1989.
19. Dunitz JD. Phase transitions in molecular crystals from a chemical viewpoint. Pure Appl Chem 1991; 63: 177-85.
20. Mathias JP, Stoddart JF. Constructing a molecular LEGO set. Chem Soc Rev 1992; 21: 215-25.
21. Dunitz JD, Taylor R. Organic fluorine hardly ever accepts hydrogen bonds. Chem Eur J 1997; 3: 89-98.
22. Braga D. 15. Crystal engineering, Where from? Where to? Chem Commun 2003: 2751-4.
23. Moulton B, Zaworotko MJ. From molecules to crystal engineering: supramolecular isom erism and polymorphism in network solids. Chem Rev 2001; 101: 1629-58.
24. Tiekink ERT, Vittal JJ, eds. Frontiers in Crystal Engineering, Chichester, UK: Wiley, 2006.
25. Desiraju GR. Crystal engineering: a holistic view. Angew Chem Int Ed 2007; 46: 8342-56.
26. Bernstein J. Polymorphism in Molecular Crystals. Oxford: Clarendon Press, 2002.
27. Hilfiker R. Polymorphism in the Pharmaceutical Industry. New York: Wiley VCH, 2006.
28. Special issue on polymorphism in crystals. Cryst Growth Des 2004; 4: 1085-444.
29. Special issue on pharmaceutical solid polymorphism in drug develop ment and regulation. Adv Drug Delivery Rev 2004; 56: 235-418.
30. Brittain HG. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker Inc., 1999.
31. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
32. Desiraju GR. Crystal and co-crystal. CrystEngComm 2003; 5: 466-7.
33. Dunitz JD. Crystal and co-crystal: a second opinion. CrystEngComm 2003; 4: 506.
34. Bond AD. What is a co-crystal? CrystEngComm 2007; 9: 833-4.
35. Aakeröy CB, Fasulo ME, Desper J. Cocrystal of salt: does it really matter? Mol Pharm 2007; 4: 317-22.
36. Stahly GP. Diversity in single- and multiple-component crystals. The search for the prevalence of polymorphs and cocrystals. Cryst Growth Des 2007; 7: 1007-26.
37. Zukerman-Schpector J, Tiekink ERT. What is a co-crystal? Zeit Fur Kristallogr 2008; 223: 233-4.
38. Parkin A, Gilmore CJ, Wilson CC. What is a co-crystal - and does it matter? Zeit Fur Kristallogr 2008: 223, 430.
39. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discov Today 2008; 13: 440-6.
40. Aakeröy CB, Beatty AM, Helfrich BA. "Total synthesis" supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules. Angew Chem Int Ed 2001; 40: 3240-2.
41. Aakeröy CB, Desper J, Helfrich BA. Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals. CrystEngComm 2004; 6: 19-24.
42. Aakeröy CB, Salmon DJ. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 2005; 7: 439-48.
43. Aakeröy CB, Hussain I, et al. Exploring the hydrogen-bond preference of N-H moieties in co-crystals assembled via O-H(Acid)...N(Py) intermolecular interactions. CrystEngComm 2007; 9: 46-54.
44. Ulrich J. Is melt crystallization a green technology? Cryst Growth Des 2004; 4: 879-90.
45. Almarsson Ö, Zaworotko MJ. Crystal Engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem Commun 2004: 1889-96.
46. Pepinsky R. Crystal engineering - a new concept in crystallography. Phys Rev 1955; 100: 971.
47. Etter MC. Hydrogen bonds as design elements in organic chemistry. J Phys Chem 1991; 95: 4601-10.
48. Zerkowski JA, MacDonald JC, Seto CT, et al. Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid:melamine complex. J Am Chem Soc 1994; 116: 2382-91.
49. Desiraju GR, ed. Crystal Design: Structure and Function, New York: Wiley, 2003.
50. Allen FH, Kennard O. Chem Des Automat News 1993; 8: 31-7.
51. Allen FH. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr 2002; B58: 380-8.
52. Zerkowski JA, Seto CT, Whitesides GM, et al. Solid-state structures of 'Rosette' and 'Crinkled Tape' motifs derived from the cyanuric acid melamine lattice. J Am Chem Soc 1992; 114: 5473-5.
53. Vishweshwar P, McMahon JA, Bis JA, et al. Pharmaceutical co-crystals. J Pharma Sci 2006; 95: 499-516.
54. Special issue on pharmaceutical co-crystals. Mol Pharm 2007; 4: 299-486.
55. Wöhler F. Untersuchungen über das Chinon. Justus Liebigs Ann Chem 1844; 51: 153.
56. Shan N, Toda F, Jones W. Mechanochemistry and Co-crystal formation: effect of solvent on reaction kinetics. Chem Commun 2002: 2372-3.
57. Trask AV, Motherwell WDS, Jones W. Solvent-drop grinding: green polymorph control of cocrystallization. Chem Commun 2004; 10: 890-1.
58. Trask AV, Jones W. Crystal engineering of organic cocrystals by the solid-state grinding approach. Top Curr Chem 2005; 254: 41-70.
59. Karki S, Friscic T, Jones W, et al. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. Mol Pharma 2007; 4: 347-54.
60. Childs SL, Rodriguez-Hornedo N, Reddy LS, et al. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm 2008; 10: 856-64.
61. Rodriguez-Hornedo N, Nehm SJ, Seefeldt KF, et al. Reaction crystallization of pharma ceutical molecular complexes. Mol Pharma 2006; 3: 362-7.
62. Remenar JF, Morissette SL, Peterson ML, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003; 125: 8456-7.
63. Childs SL, Chyall LJ, Dunlap JT, et al. Crystal Engineering Approach to Forming Cocrystals of Amine Hydrochlorides with Organic Acids. Molecular Complexes of Flu oxetine Hydrochloride with Benzoic, Succinic, and Fumaric Acids. J Am Chem Soc 2004; 126: 13335-42.
64. McNamara DP, Childs SL, Giordano J, et al. Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API. Pharma Res 2006; 23: 1888-97.
65. Hickey MB, Peterson ML, Scoppettuolo LA, et al. Performance comparison of a co-crystal of Carbamazepine with marketed product. Eur J Pharma Biopharma 2007; 67: 112-9.
66. Trask AV, Motherwell WDS, Jones W. Pharmaceutical Cocrystallization: Engineering a Remedy for Caffeine Hydration. Cryst Growth Des 2005; 5: 1013-21.
67. Trask AV. An overview of pharmaceutical cocrystals as intellectual property. Mol Pharma 2007; 4: 301-9.
68. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biophar maceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-78.
69. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceu tics classification system. New scientific approaches to international regulatory stan dards. Eur J Pharm Biopharm 2000; 50: 3-12.
70. Kanfer I. Report on the international workshop on the biopharmaceutics classification system (BCS): scientific and regulatory aspects in practice. Pharm J Pharmaceut Sci 2002; 5: 1-4.
71. Ling AR, Baker JK. Halogen derivatives of quinine. Part III. Derivatives of quinhydrone. J Chem Soc Trans 1893; 63: 1314-27.
72. Anderson JS. Structure of organic molecular compounds. Nature 1937; 140: 583-4.
73. Pekker S, Kovats E, Oszlanyi G, et al. Rotor-stator molecular crystals of fullerenes with cubane. Nat Mater 2005; 4: 764-7.
74. Hoogsteen K. The structure of crystals containing a hydrogen-bonded complex of 1-methylthymine and 9-methyladenine. Acta Crystallogr 1959; 12: 822-3.
75. Hoogsteen K. Crystal and molecular structure of a halogen-bonded complex between 1-methylthymine and 9-methyladenine. Acta Crystallogr 1963; 16: 907-16.
76. O'Brien EJ. Crystal structures of two complexes containing guanine and cytosine deriv atives. Acta Crystallogr 1967; 23: 92-106.
77. Sivakova S, Rowan SJ. Nucleobases as supramolecular motifs. Chem Soc Rev 2005; 34: 9-21.
78. von Heyden F, et al. 1934; 769, 586.
79. Amos JG, Indelicato JM, Pasini CE, et al. Bicyclic beta-lactam/paraben complexes. US5412094 (A1), JP7048383 (A), FI943081 (A), BR9402561 (A) and EP0637587 (B1), 1995.
80. Zegarac M, Mestrovic E, Dumbovic A, et al. Pharmaceutically acceptable cocrystalline forms of sildenafil. WO 2007/080362 A1, 2007.
81. Caira MR. Sulfa drugs as model cocrystal formers. Mol Pharm 2007; 4: 310-6.
82. Thayer AM. Form and function: the choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emerging as new alternatives. C & E News 2007; 85: 17-30.
83. Huang CM, Leiserowitz L, Schmidt GMJ. Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid. J Chem Soc Perkins Trans 2 1973; 5: 503-8.
84. Aakeröy CB, Beatty AM, Helfrich BA. A high-yielding supramolecular reaction. J Am Chem Soc 2002; 124: 14425-32.
85. Pedireddi VR, Chatterjee S, Ranganathan A, et al. A study of supramo lecular hydrogen bonded complexes formed by aliphatic dicarboxylic acids with azaaromatic donors. Tetrahedron 1998; 54: 9457-74.
86. Nguyen TL, Fowler FW, Lauher JW. Commensurate and incommensurate hydrogen bonds. An exercise in crystal engineering. J Am Chem Soc 2001; 123: 11057-64.
87. Walsh RDB, Bradner MW, Fleischman SG, et al. Crystal engineering of the composition of pharmaceutical phases. Chem Commun 2003: 186-7.
88. Bis JA, Vishweshwar P, Weyna D, et al. Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor. Mol Pharm 2007; 4: 401-16.
89. McMahon JA, Bis JA, Vishweshwar P, et al. Crystal engineering of the composition of pharmaceutical phases. 3 1. Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals. Fur Kristallogr 2005; 220: 340-50.
90. Sudhakar P, Srivijaya R, Sreekanth BR, et al. Carboxylic acid-pyridine supramolecular heterocatemer in a co-crystal. J Mol Struc 2008; 885: 45-9.
91. Bhogala BR, Nangia A. Ternary and quaternary co-crystals of 1,3-cis,5-cis-cyclohexanetricarboxylic acid and 4,4'-bipyridines. New J Chem 2008; 32: 800-7.
92. Broker GA, Tiekink ERT. Co-crystal formation between 2,2'-dithiodibenzoic acid and each of 4,4'-bipyridine, trans-1,2-bis (4-pyridyl)ethene and 1,2-bis(4-pyridyl)ethane. CrystEngComm 2007; 9: 1096-109.
93. Aakeröy CB, Desper J, Fasulo ME. Improving success rate of hydrogen-bond driven synthesis of co-crystals. CrystEngComm 2006; 8: 586-8.
94. Edwards MR, Jones W, Motherwell WDS. Cocrystal formation of 4-methyl and 4-chlorobenzamide with car boxylic acids: chloro/methyl interchange and crystal structure. CrystEngComm 2006; 8: 545-51.
95. Hosseini MW. Self assembly and generation of complexity. Chem Commun 2005: 5825-9.
96. Lindsey JS. Self-assembly in synthetic routes to molecular devices. Biological principles and chemical perspectives: a review. New J Chem 1991; 15: 153-80.
97. Mann S. Molecular tectonics in biomineralization and biomimetic materials chemistry. Nature 1993; 365, 499-505.
98. Calama MC, Timmerman P, Reinhoudt DN. Guest-templated selection and amplication of a receptor by noncovalent combinatorial synthesis. Angew Chem Int Ed 2000; 39: 755-8.
99. Shattock TR, Arora KK, Peddy V, et al. Hierarchy of supramolecular synthons: persistent carboxylic acid...pyridine hydrogen bonds in cocrystals that also contain a hydroxyl moiety. Cryst Growth Des 2008; 8: 4533-45.
100. Aakeröy CB, Fasulo M, Schultheiss N, et al. Structural competition between hydrogen bonds and halogen bonds. J Am Chem Soc 2007; 129: 13772-3.
101. 3-1,3,5-1.5 (4,4'-bipya): 'super trimesic acid' chicken-wire grid. Chem Commun 1996: 2655-6.
102. Vishweshear P, Nangia A, Lynch VM. Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation. Cryst Growth Des 2003; 3: 783-90.
103. Shan N, Batchelor E, Jones W. Co-crystal structures of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction. Tetrahedron Lett 2002; 43: 8721-5.
104. Arora KK, Pedireddi VR. A rational study of crystal engineering of supramolecular assemblies of 1,2,4,5-benzenetetracarboxylic acid. J Org Chem 2003; 68: 9177-85.
105. Leiserowitz L, Nader F. The molecular packing modes and the hydrogen-bonding properties of amide:carboxylic acid complexes. Acta Crystallogr 1977; B33: 2719-33.
106. Reddy LS, Nangia A, Lynch VM. Phenyl-perfluorophenyl synthon mediated cocrys tallization of carboxylic acids and amides. Cryst Growth Des 2004; 4: 89-94.
107. Biradha K, Zaworotko MJ. A supramolecular analogue of cyclohexane sustained by aromatic C-H...p interactions: complexes of 1,3,5-trihydroxybenzene with substituted pyridines. J Am Chem Soc 1998; 120: 6431-2.
108. Papaefstathiou GS, MacGillivray LR. Discrete versus infinite molecular self-assembly: control in crystalline hydrogen-bonded assemblies based on resorcinol. Org Lett 2001; 3: 3835-8.
109. Vishweshwar P, Nangia A, Lynch VM. Supramolecular synthons in phenol-isonicotinamide adducts. CrystEngComm 2003; 5: 164-8.
110. Anastas PT, Warner JC. Green Chemistry: Theory and Practice, Oxford University Press, 1998.
111. Cannon AS, Warner JC. Noncovalent derivatization: green chemistry applications of crystal engineering. Cryst Growth Des 2002; 2: 255-7.
112. Foxman BM, Guarrera DJ, Taylor LD, et al. Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquino-nes. Crystal Engineering 1998; 1: 109-18.
113. Taylor LD, Warner JC. US 5338644 A 19940816 Cont. of U.S., 5, 177262, 1994.
114. Etter MC, Frankenbach GM, Bernstein J. Solid-state nucleophilic aromatic substitution reaction of a carboxylic acid cocrystal. Tetrahedron Lett 1989; 30: 3617-20.
115. Cheney ML, McManus GJ, Perman JA, et al. The role of cocrystals in solid-state synthesis: cocrystal-controlled solid-state synthesis of imides. Cryst Growth Des 2007; 7: 616-17.
116. Pasteur L. Ann Chim Phys 1848; 24: 442.
117. Pasteur L. Ann Chim Phys 1853; 38: 437.
118. Wheeler KA, Grove RC, Davis RE, Kassel WS. Rediscovering Pasteur's quisiracemates. Angew Chem Int Ed 2008; 47: 78-81.
119. Wallach O. Justus Liebigs Ann Chem 1895; 286: 90-143.
120. Samas B, Wang W, Godrej DB. 1:1 Cocrystal of (S)-3-(ammoniomethyl)-5-methylhexanoate and (S)-mandelic acid Acta Crystallogr 2007; E63: o3938.
121. Teng MY, Sun J, Ma CA, et al. (S)-2-Hydroxy-2-phenylacetic acid-(R)-2-aminobutanoic acid-water (1/1/0.5). Acta Crystallogr 2006; E62: o2454-o2456.
122. Fischer E, Mouneyrat A. Ber Chem Ges 1900; 33: 2383.
123. Fischer E, Schoeller WA. Ann Chem 1907; 357: 1.
124. Hu ZQ, Xu DJ, Xu YZ, et al. (R)-Mandelic acid (S)-alanine hemihydrate. (b) (S)-Alanine-(s)-mandelic acid (1/1). Acta Crystallogr 2002; C58: o612-o614.
125. Hu ZQ, Xu DJ, Xu YZ. Acta Crystallogr 2004; E60: o269-o271.
126. Higuchi T, Roy K. Study of possible complex formation between macromolecules and certain pharmaceuticals. I. Polyvinylpyrrolidone with sulfathiazole, procaine hydrochloride, sodium salicylate, benzyl penicillin, chloramphenicol, mandelic acid, caffeine, theophylline, and cortisone. J Am Pharm Assoc 1954; 43: 393-7.
127. Higuchi T, Roy K. Study of possible complex formation between macromolecules and certain pharmaceuticals. II. Polyvinylpyrrolidone with p-aminobenzoic acid, aminopyrine, benzoic acid, salicylic acid, p-hydroxybenzoic acid, m-hydroxybenzoic acid, citric acid, and Phenobarbital. J Am Pharm Assoc 1954; 43: 398-401.
128. Reboul JP, Cristau B, Soyfer JC, et al. 5H-dibenz[b,f]azépine-carboxamide-5 (carbamazépine). Acta Crystallogr 1981; B37: 1844.
129. Lowes MMJ, Cairo MR, Lotter AP, et al. Physicochemical properties and x-ray structural studies of the trigonal polymorph of carbamazepine. J Pharm Sci 1987; 76: 744.
130. Grzesiak AL, Lang M, Kim K, et al. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 2003; 92: 2260.
131. Lang M, Kampf JW, Matzger AJ. Form IV of carbamazepine. J Pharm Sci 2002; 91: 1186.
132. Gelbrich T, Hursthouse MB. Systematic investigation of the relation ships between 25 crystal structures containing the carbamazepine molecule or a close analogue: a case study of the XPac method. CrystEngComm 2006; 8: 449.
133. Chang CH, Yang DSC, Yoo CS, et al. The crystal structures of (S) and (R) baclofen and carbamazepine. Acta Crystallogr 1981; A37: c71.
134. Johnston A, Florence AJ, Kennedy AR. Carbamazepine furfural hemisolvate. Acta Crystallogr 2005; E61: o1777.
135. Johnston A, Florence AJ, Kennedy AR. Carbamazepine N,N-dimethylfor-mamide solvate. Acta Crystallogr 2005; E61: o1509.
136. Lohani S, Zhang Y, Chyall LJ, et al. Carbamazepine-2,2,2-trifluoroethanol (1/1). Acta Crystallogr 2005; E61: o1310- o1312.
137. Fernandes P, Bardin J, Johnston A, et al. Carbamazepine trifluoroacetic acid solvate. (f) Solvent inclusion in the structural voids of form II carbamazepine: single crystal X-ray diffraction, NMR spectroscopy and Hirshfeld surface analysis. Acta Crystallogr 2007; E63: o4269.
138. Fabbiani FPA, Byrne LT, McKinnon JJ, et al. CrystEngComm 2007; 9: 728.
139. Johnston A, Johnston BF, Kennedy AR, et al. Tar geted crystallization of novel carbamazepine solvates based on a retrospective Random Forest classification. CrystEngComm 2008; 10: 23.
140. Reck G, Thiel W. Pharmazie 1991; 46: 509.
141. Florence AJ, Leech CK, Shankland N, et al. Control and prediction of packing motifs: a rare occurrence of carbamazepine in a catemeric configuration. CrystEngComm 2006; 8: 746.
142. Fleischman SG, Kuduva SS, McMahon JA, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 2003; 9: 909.
143. Vishweshwar P, McMahon JA, Oliveira M, et al. The predictably elusive form II of aspirin. J Am Chem Soc 2005; 127: 16802.
144. Babu NJ, Reddy LS, Nangia A. Amide N-oxide heterosynthon and amide dimer homosynthon in cocrystals of carbox amide drugs and pyridine N-oxides. Mol Pharm 2007; 4: 417.
145. Porter III WW, Elie SC, Matzger AJ. Polymorphism in carbamazepine cocrystals. Cryst Growth Des 2008; 8: 14.
146. Hilfiker R, Berghausen J, Blatter F, et al. Polymorphism - integrated approach from high-throughput screening to crystallization optimization. J Ther Ana Calor 2003; 73: 429-40.
147. Seefeldt K, Miller J, Alvarez N, Rodriguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy and calorimetry studies. J Pharma Sci 2007; 96: 1147-58.
148. Nehm SJ, Rodriguez-Spong B, Rodriguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des 2006; 6: 592-600.
149. ter Horst JH, Cains PW. Co-crystal polymorphs from a solvent-mediated transformation. Cryst Growth Des 2008; 8: 2537-42.
150. Peeteers J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-ß-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002; 91: 1414-22.
151. Francois M, Snoeckx E, Putteman P, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS Pharma Sci 2003; 5: 1-5.
152. Bak A, Gore A, Yanez E, et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and phar macokinetics. J Pharm Sci 2008; 97: 3942-56.
153. Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Des 2008; 8: 3856-62.
154. Puschner B, Poppenga RH, Lowenstine LJ, et al. Assessment of melamine and cyanuric acid toxicity in rats. J Vet Diagn Invest 2007; 19: 616-24.
155. Ranganathan A, Pedireddi VR, Rao CNR. Hydrothermal synthesis of organic channel structures: 1:1 hydrogen bonded adducts of melamine and cyanuric and trithiocyanuric acids. J Am Chem Soc 1999; 121: 1752-3.
156. Dunitz JD, Bernstein J. Disappearing polymorphs. Acc Chem Res 1995; 28: 193-200.
157. Davey RJ. Pizzas, polymorphs and pills. Chem Commun 2003: 1463-7.
158. Morrow SI. One hundred and fifty years of isomorphism. J Chem Edu 1969; 46: 580-4.
159. Wöhler F, Liebig J. Untersuchungen über das Radikal der Benzoesäure. Annal Pharm 1832; 3: 249-82.
160. Siegrist T, Kloc C, Schön JH, et al. Enhanced physical properties in a pentacene poly morph. Angew Chem Int Ed 2001; 40: 1732-6.
161. McCrone WC. Polymorphism in Physics and Chemistry of the Organic Solid State, Vol. II. In: Fox D, Labes MM, Weissberger A, eds. New York: Interscience, 1965: 725-67.
162. Caira MR. Crystalline polymorphism of organic compounds. Top Curr Chem 1998; 198: 163-208.
163. Ostwald W, Physikal Z. Studies on the formation and transformation of solid com pounds: report I. Supersaturation and practicing cooling. Chem 1897; 22: 289.
164. Boman CE, Herbertsson H, Oskarsson A. The crystal and molecular structure of a monoclinic phase of iminodiacetic acid. Acta Crystallogr 1974; B30: 378-82.
165. Bernstein J. Conformational polymorphism. III. The crystal and molecular struc tures of form II and form III of iminodiacetic acid. Acta Crystallogr 1979; B35: 360-6.
166. Graeber EJ, Morosin B. The crystal structures of 2,2', 4,4', 6,6'-hexanitroazobenzene (HNAB), forms I and II. Acta Crystallogr 1974; B30: 310-7.
167. David WIF, Shankland K, Pulham CR, et al. Polymorphism in benzamide. Angew Chem Int Ed 2005; 44: 7032-5.
168. Kalman A, Fabian L, Argay G, et al. Dipole-induced polymorphs of trans-2-hydroxycy-cloheptanecarboxylic acid with virtually the same unit cell. J Am Chem Soc 2003; 125: 34-5.
169. Matthews JH, Paul IC, Curtin DY. Configurational isomerism in crystalline forms of benzophenone anils. J Chem Soc Perkin Trans 1991; 2: 113-8.
170. Bis JA, Vishweshwar P, Middleton RA, et al. Concomitant and conformational polymor phism, conformational isomorphism, and phase relationships in 4-cyanopyridine + 4,4'-biphenol cocrystals. Cryst Growth Des 2006; 6: 1048-53.
171. 4. Bull Chem Soc Jpn 1958; 31: 611-20.
172. Sakurai T. On the refinement of the crystal structures of phenoquinone and monoclinic quinhydrone. Acta Crystallogr 1968; B24: 403-12.
173. Sakurai T. The crystal structure of the triclinic modification of quinhydrone. Acta Crystallogr 1965; B19: 320-30.
174. Schmidtmann M, Gutmann MJ, Middlemiss DS, et al. Towards proton transfer in hydrogen bonded molecular complexes: joint experimental and theoretical modeling and an energy scale for polymorphism. CrystEngComm 2007; 9: 743-5.
175. 2. J Am Chem Soc 2006; 128: 12185-91.